Corporate - Media & Press - Press Release
Arrayit Corporation's Proteomic Biomarkers Clear the Way for Pre-Symptomatic Detection of Ovarian Cancer and Other Major Diseases
Tests Will Provide Patients With an Early Diagnosis Increasing the Opportunity for Curative Measures
Press Release Source: Arrayit Corporation On Monday January 25, 2010, 7:00 am EST
SUNNYVALE, CA--(Marketwire - 01/25/10) - Arrayit Corporation (OTC.BB: ARYC - News), a leading manufacturer of products and services for disease prevention, treatment and cure, announces that Arrayit's new proteomic biomarkers will allow doctors to provide patients with a true pre-symptomatic diagnosis for Ovarian Cancer. Similar biomarkers are being developed to discover if patients are pre-symptomatic for Prostate Cancer and Parkinson's disease.
Confusion surrounds the discovery of various biomarkers that detect specific diseases and cancers. Recent breakthroughs laud biomarkers generated by tumors -- derived from patients with significant cancerous growths. Differentially, the patented Arrayit platform allows pre-symptomatic diagnosis based on biomarkers generated by the patient's immune response to the very first indication of disease.
Arrayit President, Dr. Mark Schena, told ProteoMonitor, the Global Newsweekly of Proteomics Technology, that the main difference between the company's OvaDx and the industry biomarker, CA125 for ovarian cancer, is that OvaDx "allows primary screening of all women, whereas CA125 is used mainly as a monitoring tool for women who already have ovarian cancer. OvaDx allows early-stage, pre-symptomatic detection of ovarian cancer, and as such is a true preventative medicine health care product."
Dr. Schena provided more details on OvaDx in a January 15, 2010 article in the European publication Clinica, which monitors World Technology Medical News. For access to this article, please Click Here.
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 650 products to a customer base of more than 10,000 clinics and research facilities, and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal second quarter ended June 30, 2009 and Form 10-Q for the fiscal third quarter ended September 30, 2009.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.